Traders Buy Pfizer (PFE) on Weakness

Traders bought shares of Pfizer Inc. (NYSE:PFE) on weakness during trading on Monday. $344.82 million flowed into the stock on the tick-up and $130.40 million flowed out of the stock on the tick-down, for a money net flow of $214.42 million into the stock. Of all companies tracked, Pfizer had the 4th highest net in-flow for the day. Pfizer traded down ($0.40) for the day and closed at $38.98

PFE has been the topic of several research analyst reports. Credit Suisse Group set a $45.00 target price on Pfizer and gave the company a “neutral” rating in a research note on Wednesday, December 26th. Cantor Fitzgerald set a $53.00 target price on Pfizer and gave the company a “buy” rating in a research note on Sunday, December 30th. UBS Group cut Pfizer from a “buy” rating to a “neutral” rating in a research note on Wednesday, January 23rd. ValuEngine cut Pfizer from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Finally, Zacks Investment Research cut Pfizer from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $45.61.

The company has a quick ratio of 1.33, a current ratio of 1.57 and a debt-to-equity ratio of 0.52. The stock has a market cap of $235.26 billion, a price-to-earnings ratio of 13.12, a P/E/G ratio of 2.37 and a beta of 0.75.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.01. Pfizer had a return on equity of 26.02% and a net margin of 20.79%. The company had revenue of $13.98 billion for the quarter, compared to analyst estimates of $13.92 billion. During the same period in the previous year, the company posted $0.62 earnings per share. The firm’s revenue was up 2.0% on a year-over-year basis. On average, equities analysts forecast that Pfizer Inc. will post 2.86 EPS for the current fiscal year.

In related news, EVP Douglas M. Lankler sold 5,000 shares of Pfizer stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $42.75, for a total transaction of $213,750.00. Following the sale, the executive vice president now directly owns 83,592 shares in the company, valued at $3,573,558. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rady A. Johnson sold 8,700 shares of Pfizer stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $41.13, for a total value of $357,831.00. Following the sale, the insider now owns 59,797 shares in the company, valued at $2,459,450.61. The disclosure for this sale can be found here. Insiders have sold 332,526 shares of company stock worth $14,346,539 over the last 90 days. 0.09% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Financial Gravity Wealth Inc. bought a new stake in Pfizer in the first quarter worth $33,000. Advocacy Wealth Management Services LLC lifted its holdings in shares of Pfizer by 48.2% during the fourth quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 258 shares in the last quarter. Winch Advisory Services LLC lifted its holdings in shares of Pfizer by 69.6% during the fourth quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 336 shares in the last quarter. 1 North Wealth Services LLC bought a new position in shares of Pfizer during the fourth quarter valued at $40,000. Finally, Ruggie Capital Group bought a new position in shares of Pfizer during the fourth quarter valued at $44,000. Institutional investors own 69.49% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.com-unik.info/2019/04/24/traders-buy-pfizer-pfe-on-weakness.html.

About Pfizer (NYSE:PFE)

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: What are the qualifications of a portfolio manager?

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit